Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PHRM 864 > Lecture 15 - Melanoma > Flashcards

Lecture 15 - Melanoma Flashcards

1
Q

Epidemiology

A

mortality rates have declined rapidly

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pathogenesis

A

melanocytes are dendritic pigmented cells that arise from neural-crest tissue furing early fetal development and migrate to sites within body
located in skin, uveal tract, meninges, and ectodermal mucosa
melanocytes synthesize melanin to protect tissues from UV radiation induced damage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Melanoma results from

A

the malignant transformation of skin melanocytes or from the transformation of preexisting nevocellular nevi
number of growth factors, immune factors, and tumor antigens identified in progression of melanoma: BRAF, MEK, P13K/AKT, c-KIT, cytotoxic T lymphocytes, PD-1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Cutaneous melanoma is characterized by growth patterns:

A

superficial spreading melanoma
nodular melanoma
lentigo maligna melanoma
acral lentiginous melanoma
uveal melanoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Superficial spreading melanoma

A

lesions arise from pre-existing nevus
initially appears flat but becomes irregular and asymmetrical
more common in women

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Nodular melanoma

A

strictly vertical growth, more aggressive tumors
appear dark blue-black in color and are raised and asymmetrical
more common in men

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Lentigo maligna melanoma

A

infrequent type, presents on face of elderly
tan lesion with areas of brown and black

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Acral lentiginous melanoma

A

frequently presents on palms, soles, or under nail beds; lesions have irregular convoluted borders
appear as brown stains
more common in african americans, asians, hispanics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Uveal melanoma

A

arises from pigmented epithelium of choroid
most common ocular melanoma
often metastasis in liver

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Clinical presentation

A

ABCDE: asymmetric, irregular borders, wide variety of colors, diameter of >6mm, evolution of mole may be indicative of neoplastic transformation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Diagnostic work up

A

biopsy of suspected lesion is gold standard
for suspicious lesions: wide-local excision with removal of underlying subcutaneous fat
sentinel-node biopsy for determining if melanoma has invaded lymph node beds
if melanoma is a clinical or pathologic stage IV, tumor tissue should be tested for BRAF V600E and K mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Surgery

A

margins may need to accomodate anatomical or cosmetic consideration
Mohs surgery
surgery beyond localized disease is palliative

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Radiation

A

could be offered in adjuvant setting for select pts with + lymph nodes and high risk of relapse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Adjuvant treatment

A

recommendations based on stage

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Treatment overview: stage IB or IIA (lymph node negative)

A

clinical trial or observation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Treatment overview: stage IIB or IIC (lymph node negative)

A

clinical trial, observation, pembrolizumab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Treatment overview: stage III

A

nivolumab, pembrolizumab, or dabrafenib/trametinib (if BRAF mutant), +/- radiation, or observation

18
Q

Adjuvant nivolumab

A

categroy 1 recommendation (preferred immunotherapy) in adjuvant setting

19
Q

Adjuvant pembrolizumab

A

improved recurrence free survival and reduced risk of distant metastases
similar to nivolumab in terms of efficacy and toxicity

20
Q

Adjuvant dabrafenib/trametinib

A

in completely resected, stage III disease with BRAF V600E or V600K mutations
add MEK inhibitor to prevent resistance
toxicities: pyrexia, fatigue, nausea

21
Q

First line treatment options

A

anti-PD-1 monotherapy: nivolumab, pembrolizumab
combination targeted therapy BRAF V600 mutation: dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib
certain circumstances: nivolumab/ipilimumab

22
Q

Second line treatment options

A

anti-PD-1 monotherapy: nivolumab, pembrolizumab, nivolumab/ipilimumab, pembrolizumab/low dose ipilimumab for those that have progressed on prior anti-PD-1 therapy
combination targeted therapy BRAF V600 mutation: dabrafenib/trametinib, vemurafenib/cobimetinib, encorafenib/binimetinib
chemo: dacarbazine, temozolomide, paclitaxel, albumin bound paclitaxel, carboplatin/paclitaxel

23
Q

Decision on treatment: what do we start with 1st: targeted therapy or immunotherapy?

A

targeted oral therapy for quicker onset of action - if pt has BRAF mutation

24
Q

Targeted therapies

A

BRAF: vemurafenib, dabrafenib, encorafenib
MEK: trametinib, cobimetinib, binimetinib

25
Q

Vemurafenib

A

BRAF kinase inhibitor
rare toxicity: QT prolongation; unique toxicity: development of sqaumous cell carcinoma
use in combo with cobimetinib

26
Q

Cobimetinib

A

MEK inhibitor for the treatment of unresectable or metastatic melanoma in pts with BRAF V600E or V600K
used in combo with vemurafenib to help prevent recurrence

27
Q

Dabrafenib

A

BRAF kinase inhibitor
toxicities: squamous cell carcinoma
used in combo with trametinib

28
Q

Trametinib

A

reversibly and selectively inhibits MEK 1 and 2 activation and kinase activity
MEK 1 and 2 inhibition leads to decreased cellular proliferation, cell cycle arrest, and increased apoptosis
used in combo with dabrafenib to help prevent BRAF resistance

29
Q

Encorafenib

A

BRAF kinase inhibitor
for BRAF V600E or V600K mutation, unresectable or metastatic disease
less fevers!

30
Q

Binimetinib

A

MEK-1 inhibitor
approved for BRAF V600E or V600K mutated unresectable or metastatic melanoma in combo with encorafenib
less fevers!

31
Q

PD-1 inhibitors

A

nivolumab, pembrolizumab

32
Q

CTLA-4 inhibitors

A

ipilimumab, tremelimumab

33
Q

PD-L1 inhibitors

A

atezolizumab, durvalumab

34
Q

Pembrolizumab

A

progression-free survival and overall survival longer with pembrolizumab
has less toxicity than ipilimumab

35
Q

Nivolumab/ipilimumab

A

for untreated, unresectable stage III or IV
AEs: fatigue, diarrhea, pruritis, rash, N/V, pyrexia, decreased appetite, increased LFTs, colitis, hypothyroidism

36
Q

Ipilimumab

A

CTLA-4: immune checkpoint molecule that down regulates pathways of T-cell activation
fully humanized monoclonal antibody that blocks CTLA-4 to promote antitumor immunity
in unresectable and 1st line metastatic setting
toxicities: some pts have tumor growth prior to immune system activation

37
Q

Immunotherapy response

A

immune related response criteria: response after initial increase in disease; reduction in total tumor burden after presence of new lesions
need to understand so therapy isn’t stopped based on what was thought to be progressing disease
rash, diarrhea, colitis, neuropathy, pneumonitis, musckuloskeletal pain, endocrinopathy, diabetes, hypophysitis

38
Q

Ipilimumab toxicities

A

skin: rash, vitiligo, pruritis
GI: diarrhea, colitis
liver: elevated enzymes, bilirubin, hepatitis
endocrine: hypophysitis, hypothyroidism

39
Q

Symptoms management of ipilimumab

A

grade 1: continue anti-CTLA-4 therapy, sx control
grade 2: sx control, wait until resolution to grade 1 and continue anti-CTLA-4 therapy, if no resolution to grade 1, hold anti-CTLA-4 therapy and treat like grade 3/4
grade 3/4: hold anti-CTLA-4 therapy, start steroid - budesonide, methylprednisolone, dexamethasone

40
Q

Chemo/immunotherapy

A

chemo rarely cures any pt in metastatic setting
immunotherapy: interleukin 2 (fallen out of favor) - stimulator of cytotoxic T-cells, drug associated with life threatening capillary leak syndrome; interferon alfa (fallen out of favor)

41
Q

Melanoma screening

A

montly self-exams of skin to serve as mechanism for recognizing moles or marks on skin that may be melanoma
pts with strong family history should have clinical exam by physician
high risk pts should receive yearly clinical exams

42
Q

Melanoma prevention

A

sunscreen SPF >15
avoid tanning beds and sun lamps
avoid direct exposure to sun between 10 am and 4 pm when IV rays are most intense

PHRM 864 (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions